Open an account

Bausch + Lomb

BLCO · NYSE

$17.47+$0.04 (+0.23%)TodayMarket closed ·
Prev close $17.43

About BLCO

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Employees
13,000
Headquarters
Vaughan, Ontario
Listed
May 6, 2022
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
ir.bausch.com

BLCO key statistics

Market cap
6.24B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
535.69K
Volume
412.13K
Open price
$17.26
High today
$17.50
Low today
$17.11
52 Week high
$18.92
52 Week low
$14.44

Bausch + Lomb (BLCO) at a glance

As of Oct 23, 2026, Bausch + Lomb (BLCO) shares are priced at $17.47, giving the company a market cap of 6.24B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.11 and $17.50. The current price is 2.1% above the day's low and 0.2% below its high.

Volume so far is 412.13K shares, below the average of 535.69K shares a day.

Over the past year Bausch + Lomb has ranged from $14.44 to $18.92, and now sits 68% of the way up that range.

Bausch + Lomb met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.16 per share against an estimate of $0.1561.

The average analyst price target is $19.85, 13.6% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

54%of 13 analyst ratings say Buy
  • Buy53.8%
  • Hold46.2%
  • Sell0.0%
Price target · 15 analystsAvg $19.85
Low
$16.16
Now
$17.47
High
$25.20

BLCO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 10.0% on average.

  1. Q3 FY24: reported $0.17 per share against an estimate of $0.1594
  2. Q4 FY24: reported $0.25 per share against an estimate of $0.2402
  3. Q1 FY25: reported -$0.07 per share against an estimate of $0.0269
  4. Q2 FY25: reported $0.07 per share against an estimate of $0.0688
  5. Q3 FY25: reported $0.18 per share against an estimate of $0.1659
  6. Q4 FY25: reported $0.32 per share against an estimate of $0.3586
  7. Q1 FY26: reported $0.08 per share against an estimate of $0.0586
  8. Q2 FY26: reported $0.16 per share against an estimate of $0.1561

BLCO news

  • Lekha Gupta

    Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up

  • Neeraj Jain

    Why Is Bausch + Lomb Stock Falling Monday?

  • Press releaseBusiness Wire

    Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

  • Press releaseBusiness Wire

    Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

  • Press releaseBusiness Wire

    Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

  • Vandana Singh

    ‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search

  • Press releaseBusiness Wire

    Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

  • Press releaseBusiness Wire

    Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Similar companies

Companies in the same industry as Bausch + Lomb

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.